147 related articles for article (PubMed ID: 18854550)
1. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
McCabe C; Bergmann L; Bosanquet N; Ellis M; Enzmann H; von Euler M; Jönsson B; Kallen KJ; Newling D; Nüssler V; Paschen B; de Wilde R; Wilking N; Teale C; Zwierzina H;
Ann Oncol; 2009 Mar; 20(3):403-12. PubMed ID: 18854550
[TBL] [Abstract][Full Text] [Related]
2. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
Russo P; Mennini FS; Siviero PD; Rasi G
Ann Oncol; 2010 Oct; 21(10):2081-2087. PubMed ID: 20335370
[TBL] [Abstract][Full Text] [Related]
3. Investigator-initiated trials of targeted oncology agents: why independent research is at risk?
Bergmann L; Berns B; Dalgleish AG; von Euler M; Hecht TT; Lappin GL; Reed N; Palmeri S; Smyth J; Embacher-Aichorn S; Zwierzina H;
Ann Oncol; 2010 Aug; 21(8):1573-1578. PubMed ID: 20133383
[TBL] [Abstract][Full Text] [Related]
4. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
5. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
Tirelli U; Bearz A
Ann Oncol; 2009 Aug; 20(8):1445. PubMed ID: 19654202
[No Abstract] [Full Text] [Related]
6. Market access of cancer drugs in European countries: improving resource allocation.
Pauwels K; Huys I; Casteels M; De Nys K; Simoens S
Target Oncol; 2014 Jun; 9(2):95-110. PubMed ID: 24243526
[TBL] [Abstract][Full Text] [Related]
7. Subsidised access to new melanoma drugs: in need of further innovation?
Wonder M; Fisher R
N Z Med J; 2016 Aug; 129(1440):37-54. PubMed ID: 27538038
[TBL] [Abstract][Full Text] [Related]
8. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
[TBL] [Abstract][Full Text] [Related]
9. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Janzic U; Knez L; Janzic A; Cufer T
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
[No Abstract] [Full Text] [Related]
10. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
11. European Pharmaceutical Pricing and Reimbursement--SMi's 21st Annual Meeting (October 5-6, 2015--London, UK).
Kibble A; D'Souza P
Drugs Today (Barc); 2015 Oct; 51(10):609-12. PubMed ID: 26583303
[TBL] [Abstract][Full Text] [Related]
12. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
13. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
[TBL] [Abstract][Full Text] [Related]
14. Report highlights European inequalities in access to cancer drugs.
Eur J Cancer; 2005 Dec; 41(18):2779. PubMed ID: 16408332
[No Abstract] [Full Text] [Related]
15. Early market access of cancer drugs in the EU.
Martinalbo J; Bowen D; Camarero J; Chapelin M; Démolis P; Foggi P; Jonsson B; Llinares J; Moreau A; O'Connor D; Oliveira J; Vamvakas S; Pignatti F
Ann Oncol; 2016 Jan; 27(1):96-105. PubMed ID: 26487583
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
Vassal G; Méry-Mignard D; Caulin C
Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
[TBL] [Abstract][Full Text] [Related]
17. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
18. Access to expensive anti-cancer drugs.
Mileshkin L; Sullivan D
J Law Med; 2011 Dec; 19(2):232-43. PubMed ID: 22319998
[TBL] [Abstract][Full Text] [Related]
19. A pharmacovigilance system for treatment access and medical donation programs: The Max Foundation experience.
Novakowski AK; Garcia-Gonzalez P; Wrigglesworth M; Stergachis A
Global Health; 2018 Jul; 14(1):76. PubMed ID: 30053910
[TBL] [Abstract][Full Text] [Related]
20. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
